Navigation Links
Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
Date:1/28/2008

BALTIMORE, Jan. 28 /PRNewswire/ -- Lentigen Corporation today announced the appointment of Tim Ravenscroft as chief executive officer.

David Wetherell, Lentigen's chairman, commented, "The board of Lentigen is delighted that Tim has agreed to lead Lentigen, as we are about to enter clinical trials for our first therapies later this year for Glioblastoma and GVHD. His particularly strong background and global leadership in healthcare products will serve Lentigen well as we advance with our broad set of product lines, therapeutics and collaborations."

Having most recently served as president of Bristol-Myers Squibb (BMS) Medical Imaging, Mr. Ravenscroft has more than 29 years' international experience in healthcare product development and commercial management. He has also held executive and senior positions with BMS' Global Virology Franchise, Dupont Pharmaceutical's Global HIV Business, and Glaxo Wellcome.

"Tim's strong background in HIV at BMS, DuPont and Glaxo Wellcome further bolsters Lentigen as we consider our own initiatives and collaborations in this arena," said Mr. Wetherell. "Certainly, the world needs superior solutions to address this disease, and with Tim's presence, Lentigen is better positioned than ever to play a key role."

Mr. Ravenscroft said, "Lentigen is poised to take a leading role in areas of biomedicine where Lentiviral vectors can play a decisive role. The company has a clear commitment to the improvement of health outcomes for patients in several disease areas and I am greatly looking forward to leading the corporation through its further growth and development."

Lentigen's founder Dr. Boro Dropulic, who will retain the roles of president and chief scientific officer, commented, "I am delighted that Tim has joined Lentigen and I look forward to an effective partnership that will take Lentigen to the next level."

Mr. Ravenscroft holds a bachelor's degree in applied biology from North East London University and a master's degree in information sciences from City University in the United Kingdom.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com.

Contact:

Gregory Tiberend

gtiberend@rlcinc.com

Meghan Feeks

mfeeks@rlcinc.com

Richard Lewis Communications, Inc.

212-827-0020


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the opening ... manage the new site. , Tim has 25 years of pharmaceutical experience, including ... as the Director of Manufacturing and Supplier Quality Assessment. This group is ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its ... someone who suffers from hay fever, urticaria, asthma, atopic eczema or a food ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy Regulation” ... perspectives by leading experts on the unique regulatory challenges of stem cell medical ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line ... until the first data on cross-contamination of human cell lines with HeLa cells were ... issue in cell culture labs and is associated with dramatic consequences for research. ...
Breaking Biology Technology:
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/20/2017)... ALLENTOWN, Pa. , March 20, 2017 ... PD 2.0 personal spirometer and Wellness Management System (WMS), ... Founded in 2010, PMD Healthcare is a ... Company with a mission dedicated to creating innovative solutions ... of life. With that intent focus, PMD developed the ...
Breaking Biology News(10 mins):